References
- Cystic Fibrosis Foundation. About Cystic Fibrosis – What You Need to Know, 2008. http://www.cff.org/AboutCF/
- Goss CH, Burns JL. Exacerbations in cystic fibrosis. 1: Epidemiology and pathogenesis. Thorax 2007;62:360-367
- Britto MT, Kotagal UR, Hornung RW, et al. Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis. Chest 2002;121:64-72
- Liou TG, Adler FR, Fitzsimmons SC, et al. Predictive 5-year survivorship model of cystic fibrosis. Am J Epidemiol 2001;153:345-352
- Ramsey BW. Management of pulmonary disease in patients with cystic fibrosis. N Engl J Med 1996;335:179-188
- Cystic Fibrosis Foundation. Cystic Fibrosis Foundation: Patient Registry Annual Data Report 2006. Bethesda, MD
- Ordonez CL, Henig NR, Mayer-Hamblett N, et al. Inflammatory and microbiologic markers in induced sputum after intravenous antibiotics in cystic fibrosis. Am J Respir Crit Care Med 2003;168:1471-1475
- Regelmann WE, Elliott GR, Warwick WJ, et al. Reduction of sputum Pseudomonas aeruginosa density by antibiotics improves lung function in cystic fibrosis more than do bronchodilators and chest physiotherapy alone. Am Rev Respir Dis 1990;141:914-921
- Rabin HR, Butler SM, Wohl ME, et al. Pulmonary exacerbations in cystic fibrosis. Pediatr Pulmonol 2004;37:400-406
- Lieu TA, Ray GT, Farmer G, et al. The cost of medical care for patients with cystic fibrosis in a health maintenance organization. Pediatrics 1999;103:e72
- Ouyang L, Grosse SD, Amendah DD, et al. Healthcare expenditures for privately insured people with cystic fibrosis. Pediatr Pulmonol 2009;44:989-996
- Flume PA, O'Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2007;176:957-969
- Mauskopf J, Sullivan SD, Annemans L, et al. Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices – budget impact analysis. Value Health 2007;10:336-347
- Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340:23-30
- Population Division US Census Bureau. Monthly estimates of the population by sex, race, and Hispanic origin for the United States: July 1, 2006. Available at: http://www.census.gov/popest/national/asrh/2007-nat-res.html
- Razvi S, Quittell L, Sewall A, et al. Respiratory microbiology of patients with cystic fibrosis in the United States, 1995 to 2005. Chest 2009;136:1554-1560
- Driscoll JA, Brody SL, Kollef MH. The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections. Drugs 2007;67:351-368
- Thomson PDR. Red Book for Windows. Greenwood Village, CO: Thomson, 2008
- Novartis. TOBI: Tobramycin Inhalation Solution, USP. Prescribing information, 2007
- Center for Medicare & Medicaid Services. HCPCS Alpha-Numeric Index, 2008. Available at: http://www.cms.hhs.gov/HCPCSReleaseCodeSets/Downloads/INDEX2008.pdf
- DeVilbiss Healthcare. Products: pulmonary drug delivery, 2008. Available at: http://www.devilbisshealthcare.com
- PARI Respiratory Equipment Inc. Products: the lower airway, the upper airway, 2008. Available at: http://www.pari.com/home/pari-products.htm
- American Pharmaceutical Partners Inc. Tobramycin. Prescribing information
- American Society of Health-System Pharmacists. Ceftazidime (Systemic), 2008. Available at: http://www.ashp.org/s_ashp/docs/files/practice_and_policy/ceftazidime.pdf
- Tice AD, Hoaglund PA, Nolet B, et al. Cost perspectives for outpatient intravenous antimicrobial therapy. Pharmacotherapy 2002;22:63-70S
- MAG Mutual. Physician's Fee and Coding Guide 2008, 19th edn. Atlanta, GA: MAG Mutual Healthcare Solutions, Inc., 2007
- Bloom MA, Barghout V, Kahler KH, et al. Budget impact of tegaserod on a managed care organization formulary. Am J Manag Care 2005;11:S27-34
- Cooke CE, Wong W, Lee H. Utilization and cost of sildenafil in a large managed care organization with a quantity limit on sildenafil. J Manag Care Pharm 2005;11:674-680
- Velasco MV ZI, Gonzalez A, et al. Inhaled antibiotics treatment adherence in cystic fibrosis. Paper presented at: American Thoracic Society International Conference, 2002
- Weiner JR, Toy EL, Sacco P, et al. Costs, quality of life and treatment compliance associated with antibiotic therapies in patients with cystic fibrosis: a review of the literature. Expert Opin Pharmacother 2008;9:751-766
- Modi AC, Lim CS, Yu N, et al. A multi-method assessment of treatment adherence for children with cystic fibrosis. J Cyst Fibros 2006;5:177-185
- Briesacher BA, Saiman L, Fouayzi H, et al. Adherence to tobramycin inhaled solution and health care utilization. Am J Respir Crit Care Med 2009;179:A1183
- O’Sullivan A, Sullivan JK, Higuchi K. Medication compliance and impact on health-care resource utilization and mortality among cystic fibrosis patients with P. aeruginosa. Pediatr Pulmonol 2008;S31:473-484
- Centers for Medicare & Medicaid Services. HCPCS Alpha-Numeric Index, 2008. Available at: http://www.cms.hhs.gov/HCPCSReleaseCodeSets/Downloads/INDEX2008.pdf